Lung cancer with venous thrombo-embolism: clinical characteristics
Keywords:
Pulmonary embolism, venous thrombo-embolism, lung cancerAbstract
Background: Lung cancer is the most common malignancy diagnosed in patients with venous thrombo-embolism (VTE).
Aim: To investigate clinical, biological, radiological features and survival of lung cancer patients with VTE.
Methods: Retrospective case-control study investigating biologic, clinical course and survival of 25 patients lung cancers with VTE (Group M) and 50 lung cancers without VTE (group T).
Results: The frequency of the VTE was 5.88% with 2.58% pulmonary embolism (PE). The mean age was 58 years ± 9.8 in group M and 57.9 years ± 9.6 in group T. No significant difference concerning medical or surgical history for both groups was found.
The dyspnea and chest pain were at equal frequency (63.6%). Regarding the clinical probability of the PE, it was no significant differences between the two groups. A rate of D-dimer > 0.7μg/l was more frequent among group M (75% vs 20%; p = 0.054). The most common histological type was nonsmall cell lung cancer (88%). A stage IV was significantly more frequent in group M (86.4% vs. 52.3%; p = 0.007). The mean period of survival in Group M was 10.6 ± 1.2 month and 20.2 + 1.8 month in group T; p = 0.38.
Conclusion: The VTE associated to lung cancer is under diagnosed. Prospective studies are needed to establish more adapted scores.
Downloads
References
Ma SQ, Lin Y, Ying HY, Shao YJ, Li XY, Bai CM. Solid malignancies complicated with pulmonary embolism: clinical analysis of 120 patients. Chin Med J 2010; 123: 29-23.
Chuang YM, Yu CJ. Clinical characteristics and outcomes of lung cancer with pulmonary embolism. Oncology 2009; 77: 100-6.
Descourt R, Righini M, Carrier M, Le Gal G. Place of cancer among the risk factors in venous thromboembolism. Pathol Biol (Paris) 2008; 56:178-83.
Chew HK, Davies AM, Wun T, Harvey D, Zhou H, White RH. The incidence of venous thromboembolism among patients with primary lung cancer. J Thromb Haemost 2008; 6: 601-8.
Hicks LK, Cheung MC, Ding K, et al. Venous thromboembolism and nonsmall cell lung cancer: a pooled analysis of National Cancer Institute of Canada Clinical Trials Group trials. Cancer. 2009; 115: 5516-25.
Khorana AA, Francis CW, Culakova E, Kuderer NM, Lyman GH. Frequency, risk factors, and trends for venous thromboembolism among hospitalized cancer patients. Cancer 2008; 113: 223-4.
Lee JE, Kim HR, Lee SM et al. Clinical characteristics of pulmonary embolism with underlying malignancy. Korean J Intern Med. 2010;25:66-70
Letai A, Kuter DJ. Cancer, coagulation, and anticoagulation. Oncologist 1999;4: 443-9.
Depierre A. Cancers broncho-pulmonaires: Mise au point. France: Editions John Libbey Eurotext. 2006:185-7.
Tesselaar ME, Osanto S. Risk of venous thromboembolism in lung cancer. Curr Opin Pulm Med 2007; 13: 362-7.
Sanchez O, Planquette B, Meyer G. Update on acute pulmonary embolism. Eur Respir J 2009; 18: 137-47.
Lee JW, Cha SI, Jung CY, et al. Clinical course of pulmonary embolism in lung cancer patients. Respiration 2009; 78: 42-8.
Tapson VF. The role of smoking in coagulation and thromboembolism in chronic obstructive pulmonary disease. Proc Am Thorac Soc. 2005; 2: 71-7.
Ambrosetti M, Ferrarese M, Codecasa LR, et al. Incidence of venous thromboembolism in tuberculosis patients. Respiration 2006; 73: 396.
Vaidyula VR, Criner GJ, Grabianowski C, Rao AK. Circulating tissue factor procoagulant activity is elevated in stable moderate to severe chronic obstructive pulmonary disease. Thromb Res 2009; 124: 259-61.
Ghandi R, Razak F, Tso P, Davey JR, Mahomed NN. Metabolic syndrome and the incidence of symptomatic deep vein thrombosis following total knee arthroplasty. J Rheumatol 2009; 36: 2298-301.
Heit JA, Leibson CL, Ashrani AA, Petterson TM, Bailey KR, Melton LJ. Is diabetes mellitus an independent risk factor for venous thromboembolism? Arterioscler Thromb Vasc Biol 2009; 29: 1399.
Celi A, Marconi L, Villari L, Palla A. The diagnosis of pulmonary embolism. Monaldi Arch Chest Dis 2009; 71: 47-53.
O'Connell CL, Boswell WD, Duddalwar V, et al. Unsespected pulmonary emboli in cancer patients: clinical correlates and relevance. J Clin Oncol. 2006; 24: 4928-32.
Blom JW, Doggen CJ, Osanto S, Rosendaal FR. Malignancies, prothrombotic mutations, and the risk of venous thrombosis. JAMA 2005; 293: 715-22.
Khorana AA. The NCCN Clinical practice guidelines on venous thromboembolic disease: strategies for improving VTE prophylaxis in hospitalized cancer patients. Oncologist 2007; 12: 1361-70.
Bergqvist D, Agnelli G, Cohen AT, et al; ENOXACAN II Investigators: Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancer. N Engl Med 2002; 346: 975-80.
Varki A. Trousseau's syndrome: multiple definitions and multiple mechanisms. Blood 2007; 110: 1723-9.
Tesselaar ME, Romijn FP, Van Der Linden IK, Prins FA, Bertina RM, Osanto S. Microparticle-associated tissue factor activity: a link between cancer and thrombosis? J Thromb Haemost 2007; 5: 520-7.
Pavic M, Debourdeau P, Aletti M, Farge-Bancel D, Rousset H. Maladie veineuse thromboembolique et cancer. Rev Méd Intern 2006; 27: 313-22.
Shao L, Wang ZH, Zuo JY. Clinical analysis of 23 lung cancer patients accompanied by pulmonary embolism. Ai Zheng 2009; 28: 416-9.
Righini M, Le Gal G, De Lucia S, et al. Clinical usefulness of Ddimer testing in cancer patients with suspected pulmonary embolism. Thromb Haemost 2006; 95:715-9.
Miron MJ, Perrier A, Bounameaux H, et al. Contribution of noninvasive evaluation to the diagnosis of pulmonary embolism in hospitalized patients. Eur Respir J 1999; 13: 1365-70.
Altiay G, Ciftci A, Demir M, et al. High plasma D-dimer level is associated with decreased survival in patients with lung cancer. Clin Oncol (R Coll Radiol) 2007; 19: 494-8.
Simanek R, Vormittag R, Ay C, et al. High platelet count associated with venous thromboembolism in cancer patients: results from the Vienna cancer and Thrombosis Study (CATS). J Thromb haemost 2009; 8: 114-20.
